vs
Side-by-side financial comparison of NB Bancorp, Inc. (NBBK) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
NB Bancorp, Inc. is the larger business by last-quarter revenue ($63.4M vs $60.1M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). NB Bancorp, Inc. runs the higher net margin — 12.2% vs -92.6%, a 104.7% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 33.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 22.6%).
NB Bancorp, Inc. is a U.S.-based bank holding company operating through its fully owned banking subsidiary. It provides a full range of retail and commercial banking services including various deposit products, consumer loans, residential mortgages, and small business financing solutions, primarily catering to individual and small-to-mid-sized enterprise customers across the New York metropolitan area.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NBBK vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $63.4M | $60.1M |
| Net Profit | $7.7M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 23.5% | -87.1% |
| Net Margin | 12.2% | -92.6% |
| Revenue YoY | 33.9% | 83.8% |
| Net Profit YoY | -50.6% | — |
| EPS (diluted) | $0.19 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $63.4M | $57.3M | ||
| Q3 25 | $51.7M | $51.3M | ||
| Q2 25 | $51.2M | $48.5M | ||
| Q1 25 | $47.4M | $32.7M | ||
| Q4 24 | $47.3M | $41.8M | ||
| Q3 24 | $42.6M | $33.3M | ||
| Q2 24 | $41.7M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $7.7M | $-47.5M | ||
| Q3 25 | $15.4M | $-52.9M | ||
| Q2 25 | $14.6M | $-46.6M | ||
| Q1 25 | $12.7M | $-49.5M | ||
| Q4 24 | $15.6M | $-43.3M | ||
| Q3 24 | $8.4M | $-43.6M | ||
| Q2 24 | $9.5M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 23.5% | -82.2% | ||
| Q3 25 | 38.6% | -102.6% | ||
| Q2 25 | 36.6% | -93.4% | ||
| Q1 25 | 37.1% | -143.7% | ||
| Q4 24 | 40.7% | -98.6% | ||
| Q3 24 | 36.1% | -132.0% | ||
| Q2 24 | 28.3% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 12.2% | -83.0% | ||
| Q3 25 | 29.7% | -103.1% | ||
| Q2 25 | 28.5% | -96.1% | ||
| Q1 25 | 26.7% | -151.4% | ||
| Q4 24 | 33.0% | -103.6% | ||
| Q3 24 | 19.7% | -131.2% | ||
| Q2 24 | 22.7% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.19 | $-0.73 | ||
| Q3 25 | $0.43 | $-0.82 | ||
| Q2 25 | $0.39 | $-0.75 | ||
| Q1 25 | $0.33 | $-0.81 | ||
| Q4 24 | $0.40 | $-0.71 | ||
| Q3 24 | $0.21 | $-0.73 | ||
| Q2 24 | $0.24 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $858.9M | $122.9M |
| Total Assets | $7.0B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $858.9M | $139.1M | ||
| Q3 25 | $737.0M | $148.8M | ||
| Q2 25 | $737.1M | $-11.9M | ||
| Q1 25 | $739.6M | $18.9M | ||
| Q4 24 | $765.2M | $21.7M | ||
| Q3 24 | $747.4M | $11.2M | ||
| Q2 24 | $734.3M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $7.0B | $480.2M | ||
| Q3 25 | $5.4B | $506.9M | ||
| Q2 25 | $5.2B | $372.7M | ||
| Q1 25 | $5.2B | $386.7M | ||
| Q4 24 | $5.2B | $392.3M | ||
| Q3 24 | $5.0B | $363.6M | ||
| Q2 24 | $4.8B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.8M | — |
| Free Cash FlowOCF − Capex | $57.4M | — |
| FCF MarginFCF / Revenue | 90.6% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | 7.89× | — |
| TTM Free Cash FlowTrailing 4 quarters | $117.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $60.8M | $-25.4M | ||
| Q3 25 | $24.2M | $-26.6M | ||
| Q2 25 | $27.0M | $-23.3M | ||
| Q1 25 | $9.9M | $-40.4M | ||
| Q4 24 | $43.2M | $-18.8M | ||
| Q3 24 | $8.6M | $-25.2M | ||
| Q2 24 | $24.7M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $57.4M | — | ||
| Q3 25 | $23.9M | — | ||
| Q2 25 | $26.1M | — | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | $41.3M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $23.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | 90.6% | — | ||
| Q3 25 | 46.3% | — | ||
| Q2 25 | 51.0% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 87.2% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 57.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 2.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.89× | — | ||
| Q3 25 | 1.58× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 2.77× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 2.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
